NashBio and CuriMeta partner to enhance real-world health data for life sciences

NashBio and CuriMeta have announced a collaboration aimed at expanding and diversifying advanced real-world health datasets. Both companies, leaders in the field of real-world data (RWD), will combine their expertise to create multi-modal, multi-omic datasets for life sciences research and development (R&D).

NashBio, a subsidiary of Vanderbilt University Medical Center, offers real-world clinical, genomic, and imaging data through its biobank, BioVU^®. BioVU is one of the world’s largest and most comprehensive genetic databases linked to de-identified electronic medical records (EMR) and linked bio-specimens, facilitating novel discoveries and the development of personalized therapeutics and diagnostics. NashBio serves as a commercial interface between external organizations and the institution’s resources.

Leeland Ekstrom, the Founder and CEO of NashBio, stated, “At NashBio, we say smarter data is in our DNA. Strategic collaborations with organizations like CuriMeta enhance our datasets and biobank, bringing broader, more diverse datasets to our clients. This ensures they will have the right data for their use case, which in turn achieves an optimal return on their clinical, operational and financial investment.”

The collaboration will integrate specific multi-modal, multi-omic datasets from both companies, allowing life science researchers to access diverse data regarding patient location, age, ancestry, and disease.

In order to curate, de-identify, and combine different health data repositories, such as radiology and pathology pictures, genomes, and specialist data sources, CuriMeta collaborates with academic medical centers and health systems. The collaborative efforts between CuriMeta and medical institutions produce highly explanatory datasets that are compliantly exchangeable with researchers to progress medical research and develop cures.

Davis Walp, the Founder and CEO of CuriMeta, highlighted the potential of this collaboration to enhance life sciences research. He stated, “Our primary goal at CuriMeta is to accelerate the discovery of lifesaving cures, and by partnering with leading institutions, we can expand the reach of this much-needed RWD. NashBio’s vision, mission and use cases align well with CuriMeta’s. By combining our RWD to create fit-for-purpose datasets, we bring unmatched potential to the life sciences research industry.”

By pooling their resources and expertise, NashBio and CuriMeta aim to provide researchers with comprehensive datasets to drive innovation and improve patient outcomes.